Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Determining clinically meaningful decline in preclinical Alzheimer disease.

Insel PS, Weiner M, Mackin RS, Mormino E, Lim YY, Stomrud E, Palmqvist S, Masters CL, Maruff PT, Hansson O, Mattsson N.

Neurology. 2019 Jul 9. pii: 10.1212/WNL.0000000000007831. doi: 10.1212/WNL.0000000000007831. [Epub ahead of print]

PMID:
31289148
2.

Somatic and anxiety symptoms of depression are associated with disability in late life depression.

Morin RT, Nelson C, Bickford D, Insel PS, Mackin RS.

Aging Ment Health. 2019 Apr 4:1-4. doi: 10.1080/13607863.2019.1597013. [Epub ahead of print]

PMID:
30945553
3.

Predicting diagnosis and cognition with 18F-AV-1451 tau PET and structural MRI in Alzheimer's disease.

Mattsson N, Insel PS, Donohue M, Jögi J, Ossenkoppele R, Olsson T, Schöll M, Smith R, Hansson O.

Alzheimers Dement. 2019 Apr;15(4):570-580. doi: 10.1016/j.jalz.2018.12.001. Epub 2019 Jan 25.

PMID:
30639421
4.

Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease.

Ossenkoppele R, Smith R, Ohlsson T, Strandberg O, Mattsson N, Insel PS, Palmqvist S, Hansson O.

Neurology. 2019 Feb 5;92(6):e601-e612. doi: 10.1212/WNL.0000000000006875. Epub 2019 Jan 9.

5.

Unsupervised online neuropsychological test performance for individuals with mild cognitive impairment and dementia: Results from the Brain Health Registry.

Mackin RS, Insel PS, Truran D, Finley S, Flenniken D, Nosheny R, Ulbright A, Comacho M, Bickford D, Harel B, Maruff P, Weiner MW.

Alzheimers Dement (Amst). 2018 Jun 21;10:573-582. doi: 10.1016/j.dadm.2018.05.005. eCollection 2018.

6.

Online study partner-reported cognitive decline in the Brain Health Registry.

Nosheny RL, Camacho MR, Insel PS, Flenniken D, Fockler J, Truran D, Finley S, Ulbricht A, Maruff P, Yaffe K, Mackin RS, Weiner MW.

Alzheimers Dement (N Y). 2018 Oct 15;4:565-574. doi: 10.1016/j.trci.2018.09.008. eCollection 2018.

7.

Serum Neurofilament Light Chain for Prognosis of Outcome After Cardiac Arrest.

Moseby-Knappe M, Mattsson N, Nielsen N, Zetterberg H, Blennow K, Dankiewicz J, Dragancea I, Friberg H, Lilja G, Insel PS, Rylander C, Westhall E, Kjaergaard J, Wise MP, Hassager C, Kuiper MA, Stammet P, Wanscher MCJ, Wetterslev J, Erlinge D, Horn J, Pellis T, Cronberg T.

JAMA Neurol. 2019 Jan 1;76(1):64-71. doi: 10.1001/jamaneurol.2018.3223.

PMID:
30383090
8.

Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms.

Palmqvist S, Insel PS, Zetterberg H, Blennow K, Brix B, Stomrud E; Alzheimer's Disease Neuroimaging Initiative; Swedish BioFINDER study, Mattsson N, Hansson O.

Alzheimers Dement. 2019 Feb;15(2):194-204. doi: 10.1016/j.jalz.2018.08.014. Epub 2018 Oct 23.

9.

Total Sleep Time Interacts With Age to Predict Cognitive Performance Among Adults.

Mohlenhoff BS, Insel PS, Mackin RS, Neylan TC, Flenniken D, Nosheny R, Richards A, Maruff P, Weiner MW.

J Clin Sleep Med. 2018 Sep 15;14(9):1587-1594. doi: 10.5664/jcsm.7342.

10.

Effects of APOE ε4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease.

Mattsson N, Eriksson O, Lindberg O, Schöll M, Lampinen B, Nilsson M, Insel PS, Lautner R, Strandberg O, van Westen D, Zetterberg H, Blennow K, Palmqvist S, Stomrud E, Hansson O.

Neurobiol Aging. 2018 Nov;71:81-90. doi: 10.1016/j.neurobiolaging.2018.07.003. Epub 2018 Jul 11.

PMID:
30107289
11.

Chronic depressive symptomatology and CSF amyloid beta and tau levels in mild cognitive impairment.

Gonzales MM, Insel PS, Nelson C, Tosun D, Schöll M, Mattsson N, Sacuiu S, Bickford D, Weiner MW, Mackin RS; Alzheimer's Disease Neuroimaging Initiative.

Int J Geriatr Psychiatry. 2018 Oct;33(10):1305-1311. doi: 10.1002/gps.4926. Epub 2018 Jun 28.

PMID:
29953668
12.

Amyloid pathology in the progression to mild cognitive impairment.

Insel PS, Hansson O, Mackin RS, Weiner M, Mattsson N; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2018 Apr;64:76-84. doi: 10.1016/j.neurobiolaging.2017.12.018. Epub 2017 Dec 27.

13.

Comparing 18F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease.

Mattsson N, Smith R, Strandberg O, Palmqvist S, Schöll M, Insel PS, Hägerström D, Ohlsson T, Zetterberg H, Blennow K, Jögi J, Hansson O.

Neurology. 2018 Jan 30;90(5):e388-e395. doi: 10.1212/WNL.0000000000004887. Epub 2018 Jan 10.

14.

Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations.

Lautner R, Insel PS, Skillbäck T, Olsson B, Landén M, Frisoni GB, Herukka SK, Hampel H, Wallin A, Minthon L, Hansson O, Blennow K, Mattsson N, Zetterberg H.

Alzheimers Res Ther. 2017 Oct 23;9(1):87. doi: 10.1186/s13195-017-0313-3.

15.

Serum tau and neurological outcome in cardiac arrest.

Mattsson N, Zetterberg H, Nielsen N, Blennow K, Dankiewicz J, Friberg H, Lilja G, Insel PS, Rylander C, Stammet P, Aneman A, Hassager C, Kjaergaard J, Kuiper M, Pellis T, Wetterslev J, Wise M, Cronberg T.

Ann Neurol. 2017 Nov;82(5):665-675. doi: 10.1002/ana.25067. Epub 2017 Nov 2.

16.

Cross-validation of optimized composites for preclinical Alzheimer's disease.

Donohue MC, Sun CK, Raman R, Insel PS, Aisen PS; AN-ADNI; AIBL; J-ADNI.

Alzheimers Dement (N Y). 2017 Jan;3(1):123-129. doi: 10.1016/j.trci.2016.12.001.

17.

18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease.

Mattsson N, Schöll M, Strandberg O, Smith R, Palmqvist S, Insel PS, Hägerström D, Ohlsson T, Zetterberg H, Jögi J, Blennow K, Hansson O.

EMBO Mol Med. 2017 Sep;9(9):1212-1223. doi: 10.15252/emmm.201707809.

18.

 Cortical Atrophy is Associated with Accelerated Cognitive Decline in Mild Cognitive Impairment with Subsyndromal Depression.

Gonzales MM, Insel PS, Nelson C, Tosun D, Mattsson N, Mueller SG, Sacuiu S, Bickford D, Weiner MW, Mackin RS; Alzheimer's Disease Neuroimaging Initiative.

Am J Geriatr Psychiatry. 2017 Sep;25(9):980-991. doi: 10.1016/j.jagp.2017.04.011. Epub 2017 Apr 20.

PMID:
28629965
19.

Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease.

Insel PS, Ossenkoppele R, Gessert D, Jagust W, Landau S, Hansson O, Weiner MW, Mattsson N; Alzheimer's Disease Neuroimaging Initiative.

Front Neurosci. 2017 May 17;11:281. doi: 10.3389/fnins.2017.00281. eCollection 2017.

20.

Plasma tau in Alzheimer disease.

Mattsson N, Zetterberg H, Janelidze S, Insel PS, Andreasson U, Stomrud E, Palmqvist S, Baker D, Tan Hehir CA, Jeromin A, Hanlon D, Song L, Shaw LM, Trojanowski JQ, Weiner MW, Hansson O, Blennow K; ADNI Investigators.

Neurology. 2016 Oct 25;87(17):1827-1835. Epub 2016 Sep 30.

21.

Assessing risk for preclinical β-amyloid pathology with APOE, cognitive, and demographic information.

Insel PS, Palmqvist S, Mackin RS, Nosheny RL, Hansson O, Weiner MW, Mattsson N.

Alzheimers Dement (Amst). 2016 Aug 3;4:76-84. eCollection 2016.

22.

Cognitive and functional changes associated with Aβ pathology and the progression to mild cognitive impairment.

Insel PS, Donohue MC, Mackin RS, Aisen PS, Hansson O, Weiner MW, Mattsson N; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2016 Dec;48:172-181. doi: 10.1016/j.neurobiolaging.2016.08.017. Epub 2016 Aug 26.

PMID:
27710807
23.

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease.

Mattsson N, Insel PS, Palmqvist S, Portelius E, Zetterberg H, Weiner M, Blennow K, Hansson O; Alzheimer's Disease Neuroimaging Initiative.

EMBO Mol Med. 2016 Oct 4;8(10):1184-1196. doi: 10.15252/emmm.201606540. Print 2016 Oct.

24.

Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology.

Insel PS, Mattsson N, Mackin RS, Schöll M, Nosheny RL, Tosun D, Donohue MC, Aisen PS, Jagust WJ, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2016 May 17;86(20):1887-96. doi: 10.1212/WNL.0000000000002683. Epub 2016 Apr 15.

25.

Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis.

Mattsson N, Insel PS, Palmqvist S, Stomrud E, van Westen D, Minthon L, Zetterberg H, Blennow K, Hansson O.

Nat Commun. 2016 Mar 7;7:10918. doi: 10.1038/ncomms10918.

26.

Chronic Depressive Symptomatology in Mild Cognitive Impairment Is Associated with Frontal Atrophy Rate which Hastens Conversion to Alzheimer Dementia.

Sacuiu S, Insel PS, Mueller S, Tosun D, Mattsson N, Jack CR Jr, DeCarli C, Petersen R, Aisen PS, Weiner MW, Mackin RS; Alzheimer's Disease Neuroimaging Initiative.

Am J Geriatr Psychiatry. 2016 Feb;24(2):126-35. doi: 10.1016/j.jagp.2015.03.006. Epub 2015 Mar 30.

27.

Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease.

Insel PS, Mattsson N, Mackin RS, Kornak J, Nosheny R, Tosun-Turgut D, Donohue MC, Aisen PS, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Ann Clin Transl Neurol. 2015 May;2(5):534-47. doi: 10.1002/acn3.192. Epub 2015 Mar 21.

28.

Predicting Reduction of Cerebrospinal Fluid β-Amyloid 42 in Cognitively Healthy Controls.

Mattsson N, Insel PS, Donohue M, Jagust W, Sperling R, Aisen P, Weiner MW; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Neurol. 2015 May;72(5):554-60. doi: 10.1001/jamaneurol.2014.4530.

PMID:
25775167
29.

Brain amyloid-β burden is associated with disruption of intrinsic functional connectivity within the medial temporal lobe in cognitively normal elderly.

Song Z, Insel PS, Buckley S, Yohannes S, Mezher A, Simonson A, Wilkins S, Tosun D, Mueller S, Kramer JH, Miller BL, Weiner MW.

J Neurosci. 2015 Feb 18;35(7):3240-7. doi: 10.1523/JNEUROSCI.2092-14.2015.

30.

Brain structure and function as mediators of the effects of amyloid on memory.

Mattsson N, Insel PS, Aisen PS, Jagust W, Mackin S, Weiner M; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2015 Mar 17;84(11):1136-44. doi: 10.1212/WNL.0000000000001375. Epub 2015 Feb 13.

31.

Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.

Mattsson N, Insel PS, Donohue M, Landau S, Jagust WJ, Shaw LM, Trojanowski JQ, Zetterberg H, Blennow K, Weiner MW; Alzheimer's Disease Neuroimaging Initiative*.

Brain. 2015 Mar;138(Pt 3):772-83. doi: 10.1093/brain/awu367. Epub 2014 Dec 24.

32.

The transitional association between β-amyloid pathology and regional brain atrophy.

Insel PS, Mattsson N, Donohue MC, Mackin RS, Aisen PS, Jack CR Jr, Shaw LM, Trojanowski JQ, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2015 Oct;11(10):1171-9. doi: 10.1016/j.jalz.2014.11.002. Epub 2014 Dec 9.

33.

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease.

Mattsson N, Insel PS, Landau S, Jagust W, Donohue M, Shaw LM, Trojanowski JQ, Zetterberg H, Blennow K, Weiner M; Alzheimer's Disease Neuroimaging Initiativea.

Ann Clin Transl Neurol. 2014 Aug;1(8):534-43. doi: 10.1002/acn3.81. Epub 2014 Jul 19.

34.

Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment.

Nosheny RL, Insel PS, Truran D, Schuff N, Jack CR Jr, Aisen PS, Shaw LM, Trojanowski JQ, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2015 Jan;36(1):273-82. doi: 10.1016/j.neurobiolaging.2014.07.036. Epub 2014 Aug 1.

35.

Emerging β-amyloid pathology and accelerated cortical atrophy.

Mattsson N, Insel PS, Nosheny R, Tosun D, Trojanowski JQ, Shaw LM, Jack CR Jr, Donohue MC, Weiner MW; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Neurol. 2014 Jun;71(6):725-34. doi: 10.1001/jamaneurol.2014.446.

36.

Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment.

Mattsson N, Tosun D, Insel PS, Simonson A, Jack CR Jr, Beckett LA, Donohue M, Jagust W, Schuff N, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Brain. 2014 May;137(Pt 5):1550-61. doi: 10.1093/brain/awu043. Epub 2014 Mar 12.

37.

Differences in prefrontal, limbic, and white matter lesion volumes according to cognitive status in elderly patients with first-onset subsyndromal depression.

Lee JY, Park S, Mackin S, Ewers M, Chui H, Jagust W, Insel PS, Weiner MW.

PLoS One. 2014 Jan 31;9(1):e87747. doi: 10.1371/journal.pone.0087747. eCollection 2014.

38.

Cognitive reserve associated with FDG-PET in preclinical Alzheimer disease.

Ewers M, Insel PS, Stern Y, Weiner MW; Alzheimer's Disease Neuroimaging Initiative (ADNI).

Neurology. 2013 Mar 26;80(13):1194-201. doi: 10.1212/WNL.0b013e31828970c2. Epub 2013 Mar 13.

39.

Greater regional brain atrophy rate in healthy elderly subjects with a history of cigarette smoking.

Durazzo TC, Insel PS, Weiner MW; Alzheimer Disease Neuroimaging Initiative.

Alzheimers Dement. 2012 Nov;8(6):513-9. doi: 10.1016/j.jalz.2011.10.006.

40.

Impact of apolipoprotein E4-cerebrospinal fluid β-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment.

Chiang GC, Insel PS, Tosun D, Schuff N, Truran-Sacrey D, Raptentsetsang ST, Thompson PM, Reiman EM, Jack CR Jr, Fox NC, Jagust WJ, Harvey DJ, Beckett LA, Gamst A, Aisen PS, Petersen RC, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2011 Sep;7(5):514-20. doi: 10.1016/j.jalz.2010.12.010.

41.

Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes.

Chiang GC, Insel PS, Tosun D, Schuff N, Truran-Sacrey D, Raptentsetsang S, Jack CR Jr, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Radiology. 2011 Jun;259(3):844-51. doi: 10.1148/radiol.11101637. Epub 2011 Apr 5.

42.

Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative.

Schneider LS, Insel PS, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Arch Neurol. 2011 Jan;68(1):58-66. doi: 10.1001/archneurol.2010.343.

43.

Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects.

Chiang GC, Insel PS, Tosun D, Schuff N, Truran-Sacrey D, Raptentsetsang ST, Jack CR Jr, Aisen PS, Petersen RC, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2010 Nov 30;75(22):1976-81. doi: 10.1212/WNL.0b013e3181ffe4d1. Epub 2010 Oct 27.

44.

Nonlinear time course of brain volume loss in cognitively normal and impaired elders.

Schuff N, Tosun D, Insel PS, Chiang GC, Truran D, Aisen PS, Jack CR Jr, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2012 May;33(5):845-55. doi: 10.1016/j.neurobiolaging.2010.07.012. Epub 2010 Sep 19.

45.

Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials.

Schneider LS, Dagerman K, Insel PS.

Am J Geriatr Psychiatry. 2006 Mar;14(3):191-210.

PMID:
16505124

Supplemental Content

Loading ...
Support Center